![]() Bioventix Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drug of abuse testing. | ![]() Biocept Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer. | Universal Diagnostics Universal Diagnostics (UDX) is a bioinformatics, multi-omics, and in-vitro diagnostics company that develops minimally invasive and blood-based solutions for detecting cancer. | |
Founding Date | Founding Date 2003 | Founding Date 1993 | Founding Date 2012 |
Type | Type Public | Type Public | Type Private |
Tags | |||
Locations | Locations Farnham, GB HQ | Locations San Diego, US HQ | Locations Seville, ES HQ Ljubljana, SI Madrid, ES Cambridge, US |
Employees | Employees 17 | Employees 878% decrease | Employees 1271% increase |
Valuation ($) | Valuation ($) 251.1 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) £13.1m (FY, 2025) | Revenue (est.) $25.9m (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods £1.1m (FY, 2025) | Cost of goods $28.4m (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit £12m (FY, 2025) | Gross profit ($2.5m) (FY, 2022) | Gross profit N/A |
Net income | Net income £7.6m (FY, 2025) | Net income ($32.1m) (FY, 2022) | Net income N/A |

Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer.
View companyUniversal Diagnostics (UDX) is a bioinformatics, multi-omics, and in-vitro diagnostics company that develops minimally invasive and blood-based solutions for detecting cancer.
View company